Intestine-Liver Cross-talk in Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease

Margaux Nawrot (1) , Simon Peschard (1) , Sophie Lestavel (1) , Bart Staels (1)

1 RNMCD - Récepteurs Nucléaires, Maladies Métaboliques et Cardiovasculaires - U1011

Type 2 diabetes (T2D) and Non-Alcoholic Fatty Liver Disease (NAFLD) are pathologies whose prevalence continues to increase worldwide. Both diseases are precipitated by an excessive caloric intake, which promotes insulin resistance and fatty liver. The role of the intestine and its crosstalk with the liver in the development of these metabolic diseases is receiving increasing attention. Alterations in diet-intestinal microbiota interactions lead to the dysregulation of intestinal functions, resulting in altered metabolite and energy substrate production and increased intestinal permeability. Connected through the portal circulation, these changes in intestinal functions impact the liver and other metabolic organs, such as visceral adipose tissue, hence participating in the development of insulin resistance, and worsening T2D and NAFLD. Thus, targeting the intestine may be an efficient therapeutic approach to cure T2D and NAFLD. In this review, we will first introduce the signaling pathways linking T2D and NAFLD. Next, we will address the role of the gut-liver crosstalk in the development of T2D and NAFLD, with a particular focus on the gut microbiota and the molecular pathways behind the increased intestinal permeability and inflammation. Finally, we will summarize the therapeutic strategies which target the gut and its functions and are currently used or under development to treat T2D and NAFLD.

Mots clés: NAFLD; intestine-liver cross-talk; type 2 diabetes

Domaines: Sciences du Vivant [q-bio]

Margaux Nawrot, Simon Peschard, Sophie Lestavel, Bart Staels. Intestine-Liver Cross-talk in Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease. Metabolism, 2021, pp.154844. ⟨10.1016/j.metabol.2021.154844⟩. ⟨inserm-03316034⟩